Objectives: p53 is a tumor suppressor gene and plays an important role in the etiology of breast cancer. The aim of this study is to clarify clinical significance of p53 in Ductal Carcinoma in situ (DCIS), and discuss about survival effect. Methods: The study subjects, 69 women with breast cancer, were a subset of patients operated from Jan 2005 to Dec 2006. We used a cutoff of 10% to distinguish between positive and negative p53 staining. The University of Southern California (USC)/Van Nuys Prognostic Index (VNPI) were compared with 2 categories of p53. Results: The positivity of p53 was found in 20 patients (29.0%) in DCIS. And negativity of p53 was found in 49 patients (71.0%). And 15 patients (21.7%) had a low USC/VNPI score, 42 patients (60.9%) intermediate and 12 patients (17.4%) a high score. The positivity of p53 was correlated with high USC/VNPI (P = 0.001). The univariate analysis for prognostic factors associated with Disease Free Survival (DFS) revealed that patients with p53 positivity show shorter Disease Free Survival (DFS) than patients with p53 negativity (P = 0.013) and USC/VNPI was also statistically significant (P = 0.030). Conclusions: According to our study, p53 was associated with high USC/VNPI. These findings suggest that p53 can be used to classify DCIS into at least two subtypes with differing prognoses.
Ductal Carcinoma In Situ (DCIS) of the breast is a complex and heterogeneous spectrum of pathological lesions with a widely variable malignant potential and a not yet clearly understood natural history. 1, 2 Various molecular markers have been used to predict the prognosis of DCIS. 3 Among the molecular marker, the p53 gene is a tumor suppressor gene located in the short arm of chromosome number 17. 4 It codes for a nuclear phosphoprotein that appears to play an important role in the regulation of the cell proliferation in that it controls the progression of cells from the G1 to S phase of the cell cycle. 5 Mutations in one copy of p53 and/or deletion of the normal gene occur in many human cancers including those of breast, lung, colon, and ovary, astrocytoma, and osteosarcoma, and have been shown to be associated with poor prognosis in breast cancer. 6 And the Van Nuys Prognostic Index (VNPI) is a score, developed on the basis of a multivariate retrospective analysis of some measurable prognostic factors in a large series of women. 7, 8 It is useful in predicting the risk of local recurrence (LR) in patients with conservatively treated DCIS and is therefore an aid to the complex treatment decision-making process. 9 This score combines three independent predictors of LR (tumor size, margin width and pathologic classification). The addition of scores (ranging from 1 to 3) from each of these three factors allows the identification of three Low USC/VNPI = score 4-6, intermediate USC/VNPI = score 7-9, high USC/VNPI = score 10-12. 
MATERIALS AND METHODS
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RESULTS
The main clinicopathological characteristics of the patients in our series are summarized in 7.655, P = 0.030) (Fig. 1) and positivity of p53 was also statistically significant (HR = 2.562: 95%CI of 1.089-6.029, P = 0.0137) ( Table 4) (Fig. 2) . In our study, USC/VNPI can be used to classify DCIS into at least two subtypes with differing prognosis. And p53 can also be used to predict poor prognosis. As these histological parameters are thought to predict prognosis of DCIS, p53 protein expression may also 11, 21 In breast cancer, it has been shown that p53 protein abnormalities can be present at the in situ phase and that these abnormalities are maintained throughout the stages of breast cancer progression, with no evidence being found for their acquisition during progression of a tumor from in situ to invasive disease or from invasive to metastatic disease.
Statistically significant associations were found between p53 protein expression and histological sub-type (P < 0.020), nuclear grade (P < 0.001), and mitotic index (P < 0.050).
